Want to see ACRS full AI Analyst Report?
Top Page
Aclaris Therapeutics
(NASDAQ:ACRS)
Select Model
Select Model
Rating:54Neutral
Price Target:
$6.00
▲(14.72% Upside)
Action:Reiterated
Date:08/07/26
The score is held back primarily by weak financial performance (revenue contraction, large losses, and sustained cash burn) and dilution risk from refreshed ATM financing capacity. These negatives are partially offset by strong technical momentum (price above major moving averages with positive MACD) and a relatively low-leverage balance sheet.
Positive Factors
Conservative balance sheet
Aclaris carries effectively minimal debt and meaningful equity capital, giving the company financial flexibility to fund R&D and absorb setbacks without immediate leverage. This conservative capital structure supports durable optionality for partnerships, licensing or strategic investments over the next 2–6 months.
Negative Factors
Sustained cash burn
Operating and free cash flow are deeply negative, reflecting ongoing cash burn to fund trials and development. Persistent negative cash generation will necessitate financing or partnerships to sustain the pipeline, creating execution risk and potential future dilution if catalysts are delayed or costs rise.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Aclaris carries effectively minimal debt and meaningful equity capital, giving the company financial flexibility to fund R&D and absorb setbacks without immediate leverage. This conservative capital structure supports durable optionality for partnerships, licensing or strategic investments over the next 2–6 months.
Read all positive factors
Aclaris Therapeutics (ACRS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$869.95M
Dividend YieldN/A
Average Volume (3M)1.11M
Price to Earnings (P/E)―
Beta (1Y)1.50
Revenue Growth-51.05%
EPS Growth57.25%
CountryUS
Employees71
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.58
Shares Outstanding147,198,900
10 Day Avg. Volume1,094,755
30 Day Avg. Volume1,106,653
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)3.58
Price to Sales (P/S)47.18
P/FCF Ratio-7.84
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.50Price Target Upside139.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.66
Revenue Forecast (FY)$5.98M
Aclaris Therapeutics Business Overview & Revenue Model
Company Description
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations ...
How the Company Makes Money
null...
Aclaris Therapeutics Earnings Call Summary
Earnings Call Date:May 07, 2024
(Q1-2024)
| % Change Since: |
Next Earnings Date:Nov 11, 2026
Earnings Call Sentiment Neutral
The earnings call highlights Aclaris' strong financial position and promising advancement of ATI-2138, despite some challenges in cash reserves and competitive landscape considerations. The company is making strategic moves in its drug development with a focus on efficiency and differentiation.Positive Updates
Strong Financial Position
Aclaris ended the first quarter with $161 million in cash, cash equivalents, and marketable securities, with no outstanding debt. This positions the company well financially for upcoming initiatives.
Negative Updates
Decreased Cash Reserves
Cash reserves decreased from $182 million at year-end to $161 million at the end of Q1, partly due to nonrecurring payments related to discontinued programs and severance.
Read all updates
Q1-2024 Updates
Positive
Negative
Strong Financial Position
Aclaris ended the first quarter with $161 million in cash, cash equivalents, and marketable securities, with no outstanding debt. This positions the company well financially for upcoming initiatives.
Read all positive updates
Company Guidance
During the Aclaris Therapeutics Q1 2024 earnings call, several key metrics and strategic updates were provided. The company ended the first quarter with cash, cash equivalents, and marketable securities totaling $161 million, down from $182 million at the end of the previous year. Approximately $14 million of the expenditures in the first quarter were related to nonrecurring payments. Aclaris has decided to advance ATI-2138, their oral small molecule ITK JAK3 inhibitor, into a Phase II proof-of-concept study targeting atopic dermatitis. The study is designed as an open-label trial involving 15 patients over 12 weeks, with a focus on safety, pharmacokinetics (PK), and early efficacy signals. Joseph Monahan highlighted that ATI-2138 is 44.4 times more potent than ritlecitinib in blocking ITK-dependent cytokine production and 5.4 times more potent in JAK3-dependent readouts. Financially, Aclaris is committed to maintaining a strong balance sheet with ongoing cost containment initiatives and exploring business development opportunities to source nondilutive capital.Aclaris Therapeutics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
64
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.22M | 7.83M | 18.72M | 31.25M | 29.75M | 6.76M |
| Gross Profit | 7.86M | 5.74M | 15.93M | 13.17M | 17.79M | 2.05M |
| EBITDA | -75.11M | -64.47M | -51.72M | -115.45M | -84.36M | -64.46M |
| Net Income | -75.74M | -64.92M | -132.06M | -88.48M | -86.91M | -90.86M |
Balance Sheet | ||||||
| Total Assets | 179.69M | 160.46M | 220.33M | 197.41M | 254.60M | 251.21M |
| Cash, Cash Equivalents and Short-Term Investments | 91.56M | 90.75M | 113.59M | 119.11M | 217.57M | 191.41M |
| Total Debt | 0.00 | 2.12M | 0.00 | 426.00K | 684.00K | 693.00K |
| Total Liabilities | 55.11M | 57.38M | 64.77M | 40.23M | 56.98M | 53.87M |
| Stockholders Equity | 124.58M | 103.08M | 155.55M | 157.18M | 197.62M | 197.34M |
Cash Flow | ||||||
| Free Cash Flow | -80.33M | -47.11M | -20.20M | -79.63M | -68.17M | -52.44M |
| Operating Cash Flow | -80.21M | -47.11M | -20.07M | -78.33M | -67.57M | -52.13M |
| Investing Cash Flow | -27.40M | 48.37M | -69.77M | 46.22M | 12.63M | -167.63M |
| Financing Cash Flow | 110.08M | -5.86M | 74.54M | 26.71M | 72.87M | 225.05M |
Aclaris Therapeutics Technical Analysis
Positive
5.23
Price Trends
5.11
Positive
4.66
Positive
3.84
Positive
Market Momentum
0.21
Negative
58.11
Neutral
73.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACRS, the sentiment is Positive. The current price of 5.23 is below the 20-day moving average (MA) of 5.57, above the 50-day MA of 5.11, and above the 200-day MA of 3.84, indicating a bullish trend. The MACD of 0.21 indicates Negative momentum. The RSI at 58.11 is Neutral, neither overbought nor oversold. The STOCH value of 73.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ACRS.
Aclaris Therapeutics Risk Analysis
Aclaris Therapeutics disclosed 72 risk factors in its most recent earnings report. Aclaris Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aclaris Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $750.37M | 2.36 | 96.49% | ― | 3.31% | 221.64% | |
70 Outperform | $632.60M | 106.75 | 2.61% | ― | -2.36% | -80.69% | |
63 Neutral | $958.97M | 10.48 | -54.39% | ― | ― | ― | |
56 Neutral | $1.01B | -4.04 | -128.57% | ― | ― | -9.27% | |
54 Neutral | $869.95M | -10.17 | -61.65% | ― | -51.05% | 57.25% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $347.93M | -7.67 | 21.05% | ― | ― | 43.38% |
* Healthcare Sector Average
ACRS
Aclaris Therapeutics
5.90
4.26
259.76%
OMER
Omeros
13.62
9.48
228.99%
RIGL
Rigel
41.66
8.20
24.51%
GALT
Galectin Therapeutics
3.12
-0.76
-19.59%
MDXG
MiMedx Group
4.27
-2.77
-39.35%
REPL
Replimune Group
13.67
8.68
173.95%
Aclaris Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Aclaris Updates At-The-Market Equity Sales Agreement
Positive
Aug 6, 2026
On August 6, 2026, Aclaris Therapeutics, Inc., a biopharmaceutical company focused on dermatology and immuno-inflammatory therapies, updated its equity financing arrangements by entering into a Second Amended and Restated Sales Agreement with Leer...
Executive/Board ChangesShareholder Meetings
Aclaris Stockholders Approve Directors, Pay and Auditor
Neutral
Jun 4, 2026
On June 4, 2026, Aclaris Therapeutics stockholders held their 2026 annual meeting, with about 80.55% of outstanding shares present or represented by proxy, and elected Anand Mehra, M.D., and Maxine Gowen, Ph.D., to the board to serve until the 202...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.